RARE on Nasdaq
Ultragenyx Pharmaceutical Inc.
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.3 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Kiniksa Pharmaceuticals International, plc, Axsome Therapeutics or Amicus Therapeutics, or pick any stock.
- TickerRARE on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersNovato, California1
- Incorporated inDE2
- Business address60 Leveroni Court, Novato, Ca 949492
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 55% of the revenue Ultragenyx Pharmaceutical Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $180.0M | $285.0M | $369.0M |
| Royalty | $183.0M | $275.0M | $304.0M |
Regions
North America brought in 56% of the revenue Ultragenyx Pharmaceutical Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| North America | $307.0M | $340.0M | $377.0M |
| Latin America | $77.0M | $131.0M | $170.0M |
| EMEA | $48.0M | $80.0M | $108.0M |
| Asia Pacific | $2.0M | $9.0M | $18.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development68¢$750.0M
- Selling, general and admin32¢$349.0M
- Income tax0¢$4.0M
Out of $673.0M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $673.0M | $560.0M | $434.0M |
| Cost of sales | $109.0M | $77.0M | $45.0M |
| Research and development | $750.0M | $698.0M | $648.0M |
| Selling, general and administrative | $349.0M | $321.0M | $310.0M |
| Total operating expenses | $1.2B | $1.1B | $1.0B |
| Loss from operations | -$535.0M | -$536.0M | -$569.0M |
| Interest income | $25.0M | $37.0M | $27.0M |
| Non-cash interest expense on liabilities for sales of future royalties | -$62.0M | -$63.0M | -$66.0M |
| Other income (expense) | $1.0M | -$5.0M | -$1.0M |
| Loss before income taxes | -$571.0M | -$567.0M | -$609.0M |
| (Provision for) benefit from income taxes | -$4.0M | -$2.0M | $2.0M |
| Net loss | -$575.0M | -$569.0M | -$607.0M |
| Net loss per share, basic | -$5.83 | -$6.29 | -$8.25 |
| Net loss per share, diluted | -$5.83 | -$6.29 | -$8.25 |
| Shares used in computing net loss per share, Basic | 98.6M shares | 90.5M shares | 73.5M shares |
| Shares used in computing net loss per share, Diluted | 98.6M shares | 90.5M shares | 73.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $421.0M | $174.0M | $214.0M | |
| Marketable securities | $259.0M | $436.0M | ||
| Accounts receivable, net | $158.0M | $122.0M | ||
| Inventory | $52.0M | $45.0M | ||
| Prepaid expenses and other assets | $61.0M | $40.0M | ||
| Total current assets | $951.0M | $817.0M | ||
| Property, plant, and equipment, net | $244.0M | $266.0M | ||
| Marketable securities | $57.0M | $135.0M | ||
| Intangible assets, net | $176.0M | $178.0M | ||
| Goodwill | $44.0M | $44.0M | ||
| Other assets | $60.0M | $63.0M | ||
| Total assets | $1.5B | $1.5B | ||
| Accounts payable | $31.0M | $39.0M | ||
| Accrued liabilities | $265.0M | $241.0M | ||
| Lease liabilities | $12.0M | $10.0M | ||
| Liabilities for sales of future royalties | $69.0M | $50.0M | ||
| Other liabilities | $7.0M | $4.0M | ||
| Total current liabilities | $384.0M | $344.0M | ||
| Lease liabilities | $24.0M | $30.0M | ||
| Deferred tax liabilities | $30.0M | $30.0M | ||
| Liabilities for sales of future royalties | $1.1B | $820.0M | ||
| Other liabilities | $20.0M | $17.0M | ||
| Total liabilities | $1.6B | $1.2B | ||
| Noncontrolling interest | $7.0M | $7.0M | $0 | |
| Preferred stock, par value of $0.001 per share-25.0 shares authorized; nil outstanding in 2025 and in 2024 | $0 | $0 | ||
| Common stock, par value of $0.001 per share-250.0 shares authorized; outstanding-96.6 in 2025 and 92.5 in 2024 | $0 | $0 | ||
| Treasury stock, at cost, 0.2 shares in 2025 and 0.1 shares in 2024 | -$8.0M | -$4.0M | ||
| Deferred compensation obligation | $8.0M | $4.0M | ||
| Additional paid-in capital | $4.5B | $4.2B | ||
| Accumulated other comprehensive income (loss) | $1.0M | -$1.0M | ||
| Accumulated deficit | -$4.5B | -$4.0B | ||
| Total stockholders' equity (deficit) | -$80.0M | $255.0M | $275.0M | $352.0M |
| Total liabilities, noncontrolling interest and stockholders' equity (deficit) | $1.5B | $1.5B | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 250.0M shares | 250.0M shares | ||
| Common stock, shares outstanding | 96.6M shares | 92.5M shares | ||
| Treasury stock , shares | 200.0K shares | 100.0K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $421.0M | $174.0M | $214.0M | |
| Marketable securities | $259.0M | $436.0M | ||
| Accounts receivable, net | $158.0M | $122.0M | ||
| Inventory | $52.0M | $45.0M | ||
| Prepaid expenses and other assets | $61.0M | $40.0M | ||
| Total current assets | $951.0M | $817.0M | ||
| Property, plant, and equipment, net | $244.0M | $266.0M | ||
| Marketable securities | $57.0M | $135.0M | ||
| Intangible assets, net | $176.0M | $178.0M | ||
| Goodwill | $44.0M | $44.0M | ||
| Other assets | $60.0M | $63.0M | ||
| Total assets | $1.5B | $1.5B | ||
| Accounts payable | $31.0M | $39.0M | ||
| Accrued liabilities | $265.0M | $241.0M | ||
| Lease liabilities | $12.0M | $10.0M | ||
| Liabilities for sales of future royalties | $69.0M | $50.0M | ||
| Other liabilities | $7.0M | $4.0M | ||
| Total current liabilities | $384.0M | $344.0M | ||
| Lease liabilities | $24.0M | $30.0M | ||
| Deferred tax liabilities | $30.0M | $30.0M | ||
| Liabilities for sales of future royalties | $1.1B | $820.0M | ||
| Other liabilities | $20.0M | $17.0M | ||
| Total liabilities | $1.6B | $1.2B | ||
| Noncontrolling interest | $7.0M | $7.0M | $0 | |
| Preferred stock, par value of $0.001 per share-25.0 shares authorized; nil outstanding in 2025 and in 2024 | $0 | $0 | ||
| Common stock, par value of $0.001 per share-250.0 shares authorized; outstanding-96.6 in 2025 and 92.5 in 2024 | $0 | $0 | ||
| Treasury stock, at cost, 0.2 shares in 2025 and 0.1 shares in 2024 | -$8.0M | -$4.0M | ||
| Deferred compensation obligation | $8.0M | $4.0M | ||
| Additional paid-in capital | $4.5B | $4.2B | ||
| Accumulated other comprehensive income (loss) | $1.0M | -$1.0M | ||
| Accumulated deficit | -$4.5B | -$4.0B | ||
| Total stockholders' equity (deficit) | -$80.0M | $255.0M | $275.0M | $352.0M |
| Total liabilities, noncontrolling interest and stockholders' equity (deficit) | $1.5B | $1.5B | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 250.0M shares | 250.0M shares | ||
| Common stock, shares outstanding | 96.6M shares | 92.5M shares | ||
| Treasury stock , shares | 200.0K shares | 100.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$575.0M | -$569.0M | -$607.0M |
| Stock-based compensation | $153.0M | $158.0M | $135.0M |
| Amortization of discount on marketable securities, net | -$4.0M | -$13.0M | -$13.0M |
| Depreciation and amortization | $35.0M | $36.0M | $26.0M |
| Non-cash royalty revenue | -$112.0M | -$101.0M | -$69.0M |
| Non-cash interest expense on liabilities for sales of future royalties | $62.0M | $63.0M | $66.0M |
| Other | -$2.0M | -$2.0M | $3.0M |
| Accounts receivable | -$31.0M | -$34.0M | -$23.0M |
| Inventory | -$6.0M | -$11.0M | -$7.0M |
| Prepaid expenses and other assets | -$10.0M | $12.0M | $15.0M |
| Accounts payable, accrued, and other liabilities | $24.0M | $47.0M | -$1.0M |
| Net cash used in operating activities | -$466.0M | -$414.0M | -$475.0M |
| Purchase of property, plant, and equipment | -$6.0M | -$7.0M | -$44.0M |
| Purchase of marketable securities | -$186.0M | -$409.0M | -$526.0M |
| Proceeds from sale of marketable securities | $0 | $3.0M | $51.0M |
| Proceeds from maturities of marketable securities | $444.0M | $410.0M | $696.0M |
| Payments for intangible asset | -$15.0M | -$13.0M | -$3.0M |
| Other | -$1.0M | -$2.0M | -$6.0M |
| Net cash provided by (used in) investing activities | $236.0M | -$18.0M | $168.0M |
| Proceeds from the sale of future royalties, net | $392.0M | $0 | $0 |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net | $0 | $381.0M | $326.0M |
| Proceeds from the issuance of common stock in connection with at-the-market offering, net | $80.0M | $0 | $53.0M |
| Proceeds from the issuance of common stock under equity plans, net | $6.0M | $11.0M | $8.0M |
| Proceeds from issuance of equity from noncontrolling interest | $0 | $7.0M | $0 |
| Other | $0 | $0 | $1.0M |
| Net cash provided by financing activities | $478.0M | $399.0M | $388.0M |
| Effect of exchange rate changes on cash | $4.0M | -$2.0M | $0 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $252.0M | -$35.0M | $81.0M |
| Acquired lease liabilities arising from obtaining right-of-use assets and property, plant, and equipment | $6.0M | $10.0M | $22.0M |
| Non-cash interest expense on liabilities for sales of future royalties capitalized during the year into ending property, plant and equipment | $0 | $0 | $9.0M |
| Costs of intangible assets included in accounts payable, accrued and other liabilities | $5.0M | $15.0M | $10.0M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Ultragenyx Pharmaceutical Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerEmil D. Kakkis Feb 7, 2014 to now12
- PresidentEmil D. Kakkis Feb 7, 2014 to now12
- Chief financial officerHoward Horn Oct 10, 2023 to now13
- Chief financial officerMardi Dier Oct 13, 2020 to Oct 17, 202214
- Chief financial officerShalini Sharp Feb 3, 2014 to Aug 19, 202015
- Chief operating officerWladimir Hogenhuis Oct 5, 2018 to Oct 7, 201916
Board members and other officers (24)
- EVP and Chief Medical OfficerEric Crombez May 2, 2023 to now17
- EVP & Chief Commercial OfficerErik Harris Jun 21, 2019 to now18
- EVP and Chief Medical OfficerCamille L. Bedrosian Jan 31, 2018 to Mar 3, 202319
- SVP & Chief TechOps OfficerDennis Karl Huang May 7, 2015 to now20
- OfficerJohn Richard Pinion Jul 20, 2015 to now21
- OfficerJayson Donald Alexander Dallas Aug 6, 2015 to Jun 4, 201822
- OfficerEmil D. Kakkis Jan 30, 2014 to Jan 30, 201423
- OfficerShalini Sharp Jan 30, 2014 to Oct 16, 202024
- OfficerThomas Richard Kassberg Jan 30, 2014 to Mar 4, 202525
- Controller and PAOTheodore Alan Huizenga Mar 28, 2014 to now26
- Chief Medical OfficerSunil Agarwal Aug 21, 2014 to Aug 23, 201627
- Board memberAmrit Ray Apr 22, 2022 to now28
- Board memberCorazon (corsee) D. Sanders Jun 30, 2021 to now29
- Board memberShehnaaz Suliman Feb 1, 2019 to now30
- Board memberDeborah Dunsire Apr 10, 2017 to now31
- Board memberLars Ekman Mar 21, 2016 to Jun 28, 202232
- Board memberMichael Narachi Feb 24, 2015 to now33
- Board memberDaniel G. Welch Apr 10, 2015 to now34
- Board memberClay B. Siegall Jan 30, 2014 to Aug 11, 202035
- Board memberEmil D. Kakkis Jan 30, 2014 to now23
- Board memberEran Nadav Jan 30, 2014 to Jul 17, 201436
- Board memberMarten Steen Jan 30, 2014 to Feb 3, 201437
- Board memberWilliam Aliski Jan 30, 2014 to Jun 28, 202138
- General counselKarah Herdman Parschauer Jun 22, 2016 to now39
Timeline
- Feb 7, 2014New chief executive Emil D. Kakkis becomes CEO12
Filings
379 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 81 major events, 174 insider forms, 36 large holders, 68 other. The latest 20:
- Oct 14, 20268-K EDGAR
- Oct 7, 20268-K EDGAR
- Sep 17, 20268-K EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 2, 20268-K EDGAR
- Aug 19, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 13, 2026SCHEDULE 13G EDGAR
- Aug 11, 20268-K EDGAR
- Aug 7, 2026SCHEDULE 13G EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Aug 4, 20264 EDGAR
- Aug 4, 20264 EDGAR
- Aug 3, 2026144 EDGAR
- Jul 31, 2026SCHEDULE 13G/A EDGAR
- Jul 31, 2026SCHEDULE 13G EDGAR
- Jul 30, 2026SCHEDULE 13G/A EDGAR
The 379 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
109 open-market trades by officers, directors and large owners since October 2021: 0 buys and 109 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 1,283 | $13.57 | $17.4K | Form 4 |
| Sep 3, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 161 | $13.99 | $2.3K | Form 4 |
| Aug 3, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 1,900 | $24.92 | $47.3K | Form 4 |
| Aug 3, 2026 | Horn HowardChief Financial Officer | Sale | 4,696 | $24.92 | $117.0K | Form 4 |
| Jul 1, 2026 | Horn HowardChief Financial Officer | Sale | 4,698 | $33.13 | $155.6K | Form 4 |
| Jun 15, 2026 | Sanders Corazon (Corsee) D.Director | Sale | 2,000 | $25.05 | $50.1K | Form 4 |
| Jun 15, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 1,899 | $24.62 | $46.8K | Form 4 |
| Jun 1, 2026 | Horn HowardChief Financial Officer | Sale | 4,653 | $23.77 | $110.6K | Form 4 |
| May 18, 2026 | SULIMAN SHEHNAAZDirector | Sale | 5,740 | $25.12 | $144.2K | Form 4 |
| May 5, 2026 | Crombez EricEVP and Chief Medical Officer | Sale | 344 | $24.96 | $8.6K | Form 4 |
| May 1, 2026 | Horn HowardChief Financial Officer | Sale | 4,683 | $24.90 | $116.6K | Form 4 |
| Apr 1, 2026 | Horn HowardChief Financial Officer | Sale | 4,683 | $20.97 | $98.2K | Form 4 |
| Mar 10, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 3,508 | $22.67 | $79.5K | Form 4 |
| Mar 6, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 6,018 | $21.40 | $128.8K | Form 4 |
| Mar 3, 2026 | Horn HowardChief Financial Officer | Sale | 1,635 | $22.40 | $36.6K | Form 4 |
| Mar 2, 2026 | Pinion John RichardSee Remarks | Sale | 10,029 | $22.80 | $228.7K | Form 4 |
| Mar 2, 2026 | Harris ErikEVP & Chief Commercial Officer | Sale | 10,539 | $22.80 | $240.3K | Form 4 |
| Mar 2, 2026 | KAKKIS EMIL DPresident & CEO | Sale | 54,404 | $22.80 | $1.2M | Form 4 |
| Mar 2, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 8,135 | $22.80 | $185.5K | Form 4 |
| Mar 2, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 1,632 | $22.80 | $37.2K | Form 4 |
All 109 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- RTW INVESTMENTS, LPSCHEDULE 13G, 4 filings Feb 14, 2023 to Aug 14, 202640
- AQR CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Aug 13, 202641
- State Street CorporationSCHEDULE 13G, 2 filings May 12, 2026 to Aug 7, 202642
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Jul 31, 202643
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Apr 29, 2026 to Jul 31, 202644
- BlackRockSCHEDULE 13G/A, 1 filing Jul 30, 202645
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202646
- FMR LLCSCHEDULE 13G/A, 2 filings Nov 5, 2025 to Feb 5, 202647
- SANDS CAPITAL MANAGEMENT, LLCSCHEDULE 13G/A, 2 filings Feb 13, 2024 to Feb 12, 202548
- Wellington Management CompanySCHEDULE 13G/A, 3 filings Feb 6, 2023 to Feb 10, 202549
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G/A, 4 filings Feb 14, 2022 to Feb 14, 202450
- Capital International InvestorsSC 13G/A, 2 filings Feb 11, 2022 to Dec 9, 202251
- Capital Research Global InvestorsSC 13G/A, 1 filing Oct 8, 202152
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 10,654,276 | $355.7M | 0.0% | +3,354,678 |
| Rtw Investments, LP | 7,796,895 | $260.3M | 2.2% | +4,148,100 |
| Vanguard Portfolio Management LLC | 6,790,135 | $226.7M | 0.0% | +1,404,143 |
| Aqr Capital Management LLC | 6,560,809 | $214.1M | 0.1% | +1,982,785 |
| State Street Corp | 6,158,766 | $205.6M | 0.0% | +1,137,325 |
| Vanguard Capital Management LLC | 4,296,491 | $143.5M | 0.0% | +106,660 |
| Two Sigma Investments, LP | 3,621,200 | $120.9M | 0.1% | +1,415,380 |
| Sands Capital Management, LLC | 3,158,368 | $105.5M | 0.4% | −56,165 |
| Jacobs Levy Equity Management, Inc | 2,939,719 | $98.2M | 0.4% | +1,508,648 |
| Frontier Capital Management Co LLC | 2,847,936 | $95.1M | 0.9% | +656,754 |
| Geode Capital Management, LLC | 2,578,828 | $86.1M | 0.0% | +729,437 |
| Bellevue Group AG | 1,982,775 | $66.2M | 1.4% | −397,225 |
| D. E. Shaw & Co., Inc. | 1,730,193 | $57.8M | 0.0% | +469,175 |
| Sofinnova Investments, Inc. | 1,717,505 | $57.3M | 3.1% | −1,428,383 |
| Adage Capital Partners Gp, L.l.c. | 1,580,000 | $52.8M | 0.1% | +1,100,000 |
| Mpm Bioimpact LLC | 1,418,215 | $47.4M | 2.9% | New |
| Morgan Stanley | 1,324,805 | $44.2M | 0.0% | −175,723 |
| Wellington Management Group Llp | 1,250,464 | $41.8M | 0.0% | −1,390,348 |
| Voloridge Investment Management, LLC | 1,241,556 | $41.5M | 0.2% | −185,278 |
| Bank Of America Corp /de/ | 1,148,454 | $38.3M | 0.0% | +101,908 |
| Candriam S.C.A. | 1,001,841 | $33.4M | 0.2% | −94,341 |
| Rock Springs Capital Management LP | 967,855 | $32.3M | 1.6% | −250,918 |
| Jefferies Financial Group Inc. | 929,626 | $31.0M | 0.3% | +914,138 |
| Northern Trust Corp | 920,314 | $30.7M | 0.0% | +384,748 |
| Eagle Health Investments LP | 884,121 | $29.5M | 4.9% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Sep 29, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −2.0% | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −44.7% | Report |
| Feb 18, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −38.3% | Report |
| Aug 8, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −66.0% | Report |
| Jul 15, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −68.3% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARHoward Horn, Chief financial officer
- 14SEC EDGARMardi Dier, Chief financial officer
- 15
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGARJohn Richard Pinion, Officer
- 22
- 23SEC EDGAREmil D. Kakkis, Officer
- 24SEC EDGARShalini Sharp, Officer
- 25SEC EDGARThomas Richard Kassberg, Officer
- 26
- 27SEC EDGARSunil Agarwal, Chief Medical Officer
- 28SEC EDGARAmrit Ray, Board member
- 29
- 30SEC EDGARShehnaaz Suliman, Board member
- 31SEC EDGARDeborah Dunsire, Board member
- 32SEC EDGARLars Ekman, Board member
- 33SEC EDGARMichael Narachi, Board member
- 34SEC EDGARDaniel G. Welch, Board member
- 35SEC EDGARClay B. Siegall, Board member
- 36SEC EDGAREran Nadav, Board member
- 37SEC EDGARMarten Steen, Board member
- 38SEC EDGARWilliam Aliski, Board member
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52